Lithium citrate
Product Specifications
UNSPSC Description
Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lithium-citrate.html
Solubility
10 mM in DMSO
Smiles
O=C(CC(C(O[Li])=O)(CC(O[Li])=O)O)O[Li]
Molecular Weight
209.92
References & Citations
[1]Mitra Assadi, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol. 2010 Jul;14(4):354-9.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-B1680/Lithium-citrate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-B1680/
Clinical Information
Launched
CAS Number
919-16-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7112661-01 0.05 mg (E-Coli)
Recombinant Human Fatty-acid amide hydrolase 1 (FAAH), partial
Ask
View Details MBS7112661-02 0.05 mg (Yeast)
Recombinant Human Fatty-acid amide hydrolase 1 (FAAH), partial
Ask
View Details MBS7112661-03 0.05 mg (Baculovirus)
Recombinant Human Fatty-acid amide hydrolase 1 (FAAH), partial
Ask
View Details 
MBS7112661-04 0.2 mg (E-Coli)
Recombinant Human Fatty-acid amide hydrolase 1 (FAAH), partial
Ask
View Details MBS7112661-05 0.5 mg (E-Coli)
Recombinant Human Fatty-acid amide hydrolase 1 (FAAH), partial
Ask
View Details